Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia
Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit
SERAXIS announces Appointment of Chief Medical Officer, Dr. Paul Strumph
SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.
SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.
Seraxis Inc. announces a commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF)
Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.